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Case Reportsimproved durability and performance relative to previous
VADs. Our major rationale for choosing the HeartWare
HVAD was its relatively small size and ability to be con-
tained within the pericardium, thus eliminating the potential
need to create a pocket or rotate the pump configuration. In
addition, the device’s integrated inflow cannula could de-
crease the chance of inflow obstruction related to the abnor-
mal position of the ventricles in CC-TGA. TEE guidance
ensured successful selection of the optimal insertion site
for the VAD inflow cannula.
In summary, we report a case of successful HeartWare
HVAD implantation in a patient with CC-TGA to support
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can be a fatal complication. Mechanical support to stabilize
the patient until repair or transplant may be necessary, be-
cause emergency operative repair carries a mortality as
high as 60%.1-3 The CardioWest Total Artificial Heart
(TAH-t; SynCardia Systems, Inc, Tucson, Ariz) has been
used successfully to replace the failing heart as a bridge
to transplant.4 We report the cases of the first 2 patients
treated with TAH-t implantation for unstable cardiogenic
shock resulting from post-MI VSD rupture.CLINICAL SUMMARIES
Patient 1
A68-year-oldmanwas transferred to our institution in ex-
tremis after an anterior MI and left anterior descending stent
2 placement weeks previously. Evaluation by echocardiog-
raphy showed a large pericardial effusion, a 22-mm apical
VSD, and biventricular failure. The patient had deterioration
to cardiogenic shock (systolic blood pressures less than 75mm Hg, pulmonary arterial pressure 50/20 mm Hg, central
venous pressure of 16-21 mm Hg, and pulmonary wedge
pressure of 31 mm Hg) and was intubated and transferred
to our institution on maximal pressor support. At arrival,
emergency venoarterial extracorporeal membrane oxygena-
tion (ECMO)was instituted through the femoral vessels, and
the patient’s condition was allowed to stabilize for 24 hours.
The patient underwent surgery for possible repair and device
support; however, because of extensive myocardial damage
and poor function, the decision was made intraoperatively
for TAH-t placement. The patient was extubated within 24
hours and supported for 76 days until heart transplant. He
had an uncomplicated hospital course and was discharged
2 weeks after transplant. At 3 years of follow-up, the patient
remains in excellent condition.Patient 2
A 65-year-old woman with a medical history significant
for diabetes mellitus type 2, hypertension, hyperlipidemia,
and sclerodermawas admitted to outside hospital for an acute
inferior MI. She was taken for emergency cardiac catheteri-
zation and had 2 stents placed in the proximal and mid right
dominant coronary artery. On the next day, she became dys-
pneic and hypotensive. Physical evaluation noted a newheart
murmur, and echocardiography revealed a large inferior base
VSDof 14mmwith biventricular failure. The patient was in-
tubated, an intra-aortic balloon pump was placed, and
pressor supportwasmaximized. The patient’s condition con-
tinued to deteriorate, and she was transferred to ourrdiovascular Surgery c Volume 145, Number 2 e25
Case Reportsinstitution and stabilized with femoral venoarterial extracor-
poreal membrane oxygenation. The patient was deemed
a transplant candidate and taken to the operating room 4
days later for mechanical circulatory support. Intraoperative
evaluation noted extensive bilateral myocardial necrosis and
friability, including the left apex, septum, and a large portion
of the right ventricle. The decision was made for TAH-t
placement. On postoperative days 0, 1, and 3, the patient re-
quired reexploration and evacuation of hematoma for bleed-
ing and mediastinal hematoma. She continued to progress to
multiorgan failure, coagulopathy, and vasodilatory shock
despite multipressor support. Evidence of sepsis, including
bilateral pneumonia and lactic acidosis, led to discontinu-
ance of support 9 days after TAH-t implantation.
DISCUSSION
VSDs are rare, life-threatening complications that occur
after MI in 1% to 2% of patients.1 As many as 90% of pa-
tients would die without intervention; however, mortality
with emergency surgical or percutaneous repair is still
greater than 50%.1 Patients who have cardiogenic shock
and biventricular failure develop requiremechanical support
for stabilization until definitive repair or transplant can be
performed. Implantable left ventricular assist devices have
been successfully used as a bridge to transplant after post-
MI VSD.3 Securing the inflow cannula to infarcted apical
myocardium can be technically difficult, and post-MI ven-
tricular arrhythmias may complicate left ventricular assist
device management. Severe valvular insufficiency and
post-MI extensive left ventricular myocardial loss with
poor function may favor replacement of both ventricles.
The TAH-t is a pneumatic, pulsatile pump that replaces
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patients in end-stage cardiogenic shock by providing imme-
diate hemodynamic stabilization and end-organ perfusion
until cardiac transplant can occur. Survivals to transplant
with the TAH-t as great as 79% have been reported,4 com-
parable to biventricular support survival of 56% at 6
months.5 Use of the TAH-t currently obligates the patient
to undergo a transplant, and every effort should be made
to preserve the patient’s own myocardium. All mechanical
support devices possess inherent risk factors, including
infection, thromboembolism, and hemorrhage.
We present the first 2 cases of patients with post-MI VSD
rupture with end-stage cardiogenic shock to undergo TAH-t
placement. TAH-t support is an alternative option to biven-
tricular support devices for critically unstable patients with
post-MIVSDandextensiveventricularmyocardial loss.Mor-
talitywas 50% in this small series, which underlines the com-
plexity of predicting outcomes in this patient population.References
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Libman-Sacks endocarditisNaritomo Nishioka, MD, Naoto Morimoto, MD, PhD, Masato Yoshida, MD, PhD, and
Nobuhiko Mukohara, MD, PhD, Himeji-city, JapanLibman-Sacks endocarditis, first described by Libman and
Sacks1 in 1924, is the pathognomonic valvular lesion of sys-
temic lupus erythematosus or antiphospholipid antibody syn-
drome that may develop on the endocardial surface of the
heart. These lesions have a propensity toward formation on
the left valves, particularly the ventricular surface of the mi-
tral valve.We report the case of a 26-year-oldwomanwithout
a history of cardiac diseasewhowas seen for an atypical form
of Libman-Sacks endocarditis. The disease progressed in anery c February 2013
